Voloridge Investment Management LLC Sells 205,575 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Voloridge Investment Management LLC trimmed its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 21.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 769,725 shares of the company's stock after selling 205,575 shares during the period. Voloridge Investment Management LLC owned approximately 0.56% of Vir Biotechnology worth $5,650,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Baker BROS. Advisors LP acquired a new position in Vir Biotechnology during the 4th quarter worth $7,961,000. Artisan Partners Limited Partnership acquired a new position in shares of Vir Biotechnology in the 4th quarter worth approximately $6,742,000. Point72 Asset Management L.P. grew its position in shares of Vir Biotechnology by 16,169.5% in the 4th quarter. Point72 Asset Management L.P. now owns 848,454 shares of the company's stock worth $6,228,000 after acquiring an additional 843,239 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Vir Biotechnology by 58.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock worth $14,059,000 after acquiring an additional 703,360 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Vir Biotechnology by 55.3% in the fourth quarter. Millennium Management LLC now owns 1,715,083 shares of the company's stock worth $12,589,000 after purchasing an additional 610,367 shares during the period. 65.32% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Vir Biotechnology

In other news, CEO Backer Marianne De sold 79,712 shares of the stock in a transaction on Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total transaction of $474,286.40. Following the completion of the sale, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. This represents a 9.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 16.00% of the company's stock.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock traded down $0.33 during trading on Friday, hitting $4.86. The stock had a trading volume of 2,399,232 shares, compared to its average volume of 1,396,804. The firm has a market cap of $671.84 million, a P/E ratio of -1.24 and a beta of 1.36. The business has a fifty day moving average of $5.50 and a two-hundred day moving average of $7.52. Vir Biotechnology, Inc. has a fifty-two week low of $4.32 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The business had revenue of $3.03 million during the quarter, compared to analyst estimates of $8.59 million. During the same period in the previous year, the company posted ($0.48) earnings per share. Vir Biotechnology's revenue was down 94.6% compared to the same quarter last year. As a group, research analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on VIR shares. HC Wainwright reaffirmed a "buy" rating and issued a $110.00 price objective on shares of Vir Biotechnology in a report on Friday, February 28th. Needham & Company LLC restated a "buy" rating and issued a $14.00 target price on shares of Vir Biotechnology in a research note on Thursday, May 22nd. Barclays lifted their target price on Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, The Goldman Sachs Group reduced their price objective on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $32.86.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).